Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its earnings to grow at a solid clip.
Metric
Q4 2017
Source: Fool.com
Becton, Dickinson & Co. Stock
€210.10
-0.100%
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Becton, Dickinson & Co..
With a target price of 265 € there is a positive potential of 26.13% for Becton, Dickinson & Co. compared to the current price of 210.1 €.